Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma
Authors:
Open Access
- 23 June 2016
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 127 (25) , 3127-3132
Abstract
Response assessment in lymphoma relies on imaging scans that do not capture biologic processes at the molecular level. Monitoring circulating tumor DNA (ctDNA) with next-generation sequencing–based assays can detect recurrent disease prior to scans and “liquid biopsies” for somatic mutations address tumor heterogeneity, clonal evolution, and mechanisms of resistance to guide precision treatment. Preanalytic collection and processing procedures should be validated and standardized. We describe emerging applications of ctDNA monitoring including real-time analysis of tumor dynamics, preclinical disease detection, and precision-directed treatment paradigms.Keywords
This publication has 45 references indexed in Scilit:
- A novel blood collection device stabilizes cell-free RNA in blood during sample shipping and storageBMC Research Notes, 2013
- Circulating cell free DNA: Preanalytical considerationsClinica Chimica Acta, 2013
- Detection of circulating tumour DNA in patients with aggressive B‐cell non‐Hodgkin lymphomaBritish Journal of Haematology, 2013
- Cell-free nucleic acids as biomarkers in cancer patientsNature Reviews Cancer, 2011
- Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup studyBlood, 2010
- Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2010
- Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomasAnnals of Oncology, 2009
- Computed Tomography — An Increasing Source of Radiation ExposureNew England Journal of Medicine, 2007
- Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphomaBlood, 2003
- Immunoglobulin-Gene Rearrangements as Unique Clonal Markers in Human Lymphoid NeoplasmsNew England Journal of Medicine, 1983